ARCA biopharma, Inc.687604108US687604108708/22/2024To approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger;SECTION 14A SAY-ON-PAY VOTES866375.0000000FOR866375.000000FORKalVista Pharmaceuticals, Inc.483497103US483497103210/03/2024Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES6249731.0000000FOR6249731.000000FORDianthus Therapeutics, Inc.252828108US252828108005/22/2025To approve, on an advisory basis, the compensation paid to our named executive officers; andSECTION 14A SAY-ON-PAY VOTES1744373.0000000FOR1744373.000000FORSpyre Therapeutics, Inc.00773J202US00773J202405/29/2025To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES0.0000000Dyne Therapeutics, Inc.26818M108US26818M108005/30/2025To vote, on an advisory basis, to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES2173913.0000000FOR2173913.000000FORDyne Therapeutics, Inc.26818M108US26818M108005/30/2025To hold an advisory vote on the frequency of future advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES2173913.0000000ONE YEAR2173913.000000FOROruka Therapeutics, Inc.687604108US687604108706/02/2025To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES0.0000000Oruka Therapeutics, Inc.687604108US687604108706/02/2025To vote, on a non-binding, advisory basis, on the frequency of future advisory votes to approve compensation for our named executive officers.SECTION 14A SAY-ON-PAY VOTES0.0000000Cogent Biosciences, Inc.19240Q201US19240Q201206/04/2025Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES5684411.0000000FOR5684411.000000FORGlycoMimetics, Inc.G2545C104KYG2545C104206/05/2025Approve, on an advisory basis, certain compensation arrangements for GlycoMimetics' named executive officers that are based on or otherwise relate to the Merger.SECTION 14A SAY-ON-PAY VOTES3000000.0000000FOR3000000.000000FORGlycoMimetics, Inc.G2545C104KYG2545C104206/05/2025Approve, on an advisory basis, the compensation of GlycoMimetics' named executive officers.SECTION 14A SAY-ON-PAY VOTES3000000.0000000FOR3000000.000000FORSavara Inc.805111101US805111101606/05/2025To approve, on an advisory basis, the compensation of our named executives.SECTION 14A SAY-ON-PAY VOTES3467547.0000000FOR3467547.000000FORSavara Inc.805111101US805111101606/05/2025To indicate, on an advisory basis, the preferred frequency of holding an advisory vote on the compensation of our named executives.SECTION 14A SAY-ON-PAY VOTES3467547.0000000ONE YEAR3467547.000000FORAbivax SA00370M103US00370M103606/06/2025Approve Compensation of Marc de Garidel, Acting Chairman of the Board and CEOSECTION 14A SAY-ON-PAY VOTES1345780.0000000FOR1345780.000000FORAbivax SA00370M103US00370M103606/06/2025Approve Compensation of Sylvie Gregoire, Chairwoman of the BoardSECTION 14A SAY-ON-PAY VOTES1345780.0000000FOR1345780.000000FORApplied Therapeutics, Inc.03828A101US03828A101606/09/2025To approve (on a non-binding advisory basis) the compensation of our named executive officers as described in the accompanying materials.SECTION 14A SAY-ON-PAY VOTES5360425.0000000FOR5360425.000000FORApplied Therapeutics, Inc.03828A101US03828A101606/09/2025To approve (on a non-binding advisory basis) the frequency of an advisory vote on the compensation of our named executive officers in future years.SECTION 14A SAY-ON-PAY VOTES5360425.0000000ONE YEAR5360425.000000FORAstria Therapeutics, Inc.04635X102US04635X102806/11/2025The approval, by non-binding advisory vote, of our executive compensation.SECTION 14A SAY-ON-PAY VOTES2457348.0000000FOR2457348.000000FORDBV Technologies SA23306J309US23306J309506/11/2025Approval of the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2024, to Mr. Michel de Rosen, Chairman of the Board of DirectorsSECTION 14A SAY-ON-PAY VOTES68701.0000000FOR68701.000000FORDBV Technologies SA23306J309US23306J309506/11/2025Approval of the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2024, to Mr. Daniel Tasse, Chief Executive OfficerSECTION 14A SAY-ON-PAY VOTES68701.0000000FOR68701.000000FORDBV Technologies SA23306J309US23306J309506/11/2025Advisory opinion on the compensation of named executive officers other than the Chief Executive OfficerSECTION 14A SAY-ON-PAY VOTES68701.0000000FOR68701.000000FOROcular Therapeutix, Inc.67576A100US67576A100706/11/2025To approve an advisory vote on named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES12762462.0000000FOR12762462.000000FORTenax Therapeutics, Inc.88032L605US88032L605606/11/2025Approval, on an advisory basis, of Tenax Therapeutics, Inc.'s 2024 named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES208333.0000000FOR208333.000000FORTenax Therapeutics, Inc.88032L605US88032L605606/11/2025Approval, on an advisory basis, on the frequency of future advisory votes on named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES208333.0000000TWO YEARS208333.000000FORTrevi Therapeutics, Inc.89532M101US89532M101806/11/2025Approval, on an advisory basis, of the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTES58999.0000000FOR58999.000000FORTrevi Therapeutics, Inc.89532M101US89532M101806/11/2025Approval, on an advisory basis, of the frequency of future advisory votes to approve the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTES58999.0000000ONE YEAR58999.000000FORCullinan Therapeutics, Inc.230031106US230031106306/12/2025Proposal to vote, on an advisory basis, to approve our named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES1379965.0000000FOR1379965.000000FORCullinan Therapeutics, Inc.230031106US230031106306/12/2025Proposal to vote, on an advisory basis, on the frequency of future advisory votes on our named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES1379965.0000000ONE YEAR1379965.000000FORMersana Therapeutics, Inc.59045L106US59045L106106/12/2025To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES2539442.0000000FOR2539442.000000FORSolid Biosciences Inc.83422E204US83422E204606/12/2025The approval of an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTES1480202.0000000FOR1480202.000000FORApogee Therapeutics, Inc.03770N101US03770N101906/17/2025Vote on the frequency of future advisory votes to approve our named executive officers compensation.SECTION 14A SAY-ON-PAY VOTES1750000.0000000ONE YEAR1750000.000000FORCidara Therapeutics, Inc.171757206US171757206906/18/2025Approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in: the proxy statement.SECTION 14A SAY-ON-PAY VOTES657548.0000000FOR657548.000000FORViridian Therapeutics, Inc.92790C104US92790C104506/20/2025To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES3882709.0000000FOR3882709.000000FORPraxis Precision Medicines, Inc.74006W207US74006W207006/26/2025To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2025 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.SECTION 14A SAY-ON-PAY VOTES244858.0000000FOR244858.000000FOR